Improving the developability profile of pyrrolidine progesterone receptor partial agonists.
Kallander, L.S., Washburn, D.G., Hoang, T.H., Frazee, J.S., Stoy, P., Johnson, L., Lu, Q., Hammond, M., Barton, L.S., Patterson, J.R., Azzarano, L.M., Nagilla, R., Madauss, K.P., Williams, S.P., Stewart, E.L., Duraiswami, C., Grygielko, E.T., Xu, X., Laping, N.J., Bray, J.D., Thompson, S.K.(2010) Bioorg Med Chem Lett 20: 371-374
- PubMed: 19926282 
- DOI: https://doi.org/10.1016/j.bmcl.2009.10.092
- Primary Citation of Related Structures:  
3KBA - PubMed Abstract: 
The previously reported pyrrolidine class of progesterone receptor partial agonists demonstrated excellent potency but suffered from serious liabilities including hERG blockade and high volume of distribution in the rat. The basic pyrrolidine amine was intentionally converted to a sulfonamide, carbamate, or amide to address these liabilities ...